Clinical trials: Obesity, Overweight
Overweight, Obesity
Safety and Efficacy of Litramine in Overweight and Obese Subjects
Preparations that bind to nutritional fat and inhibit its absorption could be decisively meaningful for the regulation of bodyweight or obesity.
- Conditions
- Overweight, Obesity, Weight Loss
- Trial name
- NCT01233349
- Testing
- Litramine
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity or Overweight
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for chronic weight management in adult…
- Trial name
- NCT07081958
- Testing
- RO7795081
- Where
- 36 sites in United States
- Volunteers
- 352 people
- Sponsor
- Hoffmann-La Roche
Crohn's Disease, Obesity or Overweight
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and…
- Trial name
- COMMIT-CD (NCT06937099)
- Testing
- Mirikizumab, Tirzepatide
- Where
- 183 sites in United States, Austria and 20 more
- Volunteers
- 290 people
- Sponsor
- Eli Lilly and Company
Overweight , Obesity
Efficacy and Safety of ZT006 in Overweight and Obese Participants
This study is being conducted to evaluate the efficacy and safety of ZT006 tablet in participants with overweight and obesity. In addition to dietary caloric restriction and increased physical activity, study participants will…
- Trial name
- NCT07230132
- Testing
- ZT006
- Where
- 12 sites in China
- Volunteers
- 184 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity
First in Human Study in Subjects With Obesity, But Otherwise Healthy
This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
- Trial name
- NCT06252220
- Testing
- DA-1726
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Overweight or Obesity
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the…
- Trial name
- NCT07294235
- Testing
- BGM1812
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Overweight and Obesity
Extension Study of Gelesis100 on Body Weight
This study is designed to assess the effect of Gelesis100 on body weight after an additional exposure of 24 weeks in subjects who completed the 24-week treatment period, and had at least 3% weight loss, in the Gelesis Loss Of…
- Trial name
- GLOW-EX (NCT03021291)
- Testing
- Gelesis100 (2.25 g)
- Where
- 16 sites in United States, Czechia and 3 more
- Volunteers
- 36 people
- Sponsor
- Gelesis, Inc.
Overweight , Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults
The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.
- Trial name
- NCT07487376
- Testing
- IBIO-600
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- iBio, Inc.
Obesity
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in…
- Trial name
- NCT06771115
- Testing
- VTX3232 30 mg, VTX3232 30 mg in combination with semaglutide
- Where
- 14 sites in United States
- Volunteers
- 175 people
- Sponsor
- Zomagen Biosciences Ltd.
Obesity, Hyperglycemia
The Effect of a Bifidobacterium and Polydextrose on Body Fat Mass
Obesity is a major problem worldwide, and it is related to abnormalities in glucose and lipid metabolism. The purpose of this study is to investigate the effect of a dietary supplement containing probiotic (Bifidobacterium…
- Conditions
- Obesity, Hyperglycemia, Insulin Resistance
- Trial name
- MetSProb (NCT01978691)
- Testing
- Bifidobacterium animalis ssp. lactis 420, Polydextrose
- Where
- 4 sites in Finland
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Danisco
Obesity, Binge-Eating Disorder
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
The purpose of this study is to evaluate the safety and effectiveness of topiramate compared to placebo in reducing the number of binge days in patients with moderate to severe binge-eating disorder associated with obesity.
- Trial name
- NCT00210808
- Testing
- topiramate
- Volunteers
- 407 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight, Obesity
Dietary Supplements and Personal Energy Tracking Device to Promote and Maintain Healthy Weight
Excessive body weight is becoming a concern around the world, for example over half of the American adult population is overweight or obese.
- Trial name
- NCT00502658
- Testing
- Dietary supplement containing vitamins, minerals, and herbs, Shakes with nutrients and herbs, Control dietary supplement
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection
- Trial name
- NCT07842640
- Testing
- ASC35 Injection B, for subcutaneous use, Tirzepatide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Overweight , Obesity
Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity
This study is designed as a preliminary investigation to evaluate the weight-loss efficacy and safety of AKM Lab-01 in an overweight or obese population.
- Trial name
- NCT07331974
- Testing
- AKM Lab-01
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Moon (Guangzhou) Biotechnology Co., Ltd.
Obesity, Overweight
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity.
- Trial name
- NCT07476118
- Testing
- Brenipatide
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
High Density Lipoprotein Turnover
The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.
- Trial name
- NCT00408148
- Testing
- Rimonabant
- Where
- 4 sites in Australia, Finland and 2 more
- Volunteers
- 64 people
- Sponsor
- Sanofi
Obesity
A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects
The purpose of this study was to assess the effect of naltrexone SR/bupropion SR (NB) on brain function in response to food cues using functional magnetic resonance imaging in overweight or obese subjects.
- Trial name
- NCT00711477
- Testing
- Naltrexone SR 32 mg/bupropion SR 360 mg/day, fMRI scan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
Obalon Navigation/Touch System Post-Approval Study
Post-approval study for the Obalon Navigation/Touch System (NTS)
- Trial name
- NTS PAS (NCT04095481)
- Testing
- Obalon Navigation/Touch System
- Where
- 2 sites in United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Obalon Therapeutics, Inc.
Obesity, Morbid
The ReNEW Study: Maestro® New Enrollment Post-Approval Study Protocol
This is a five-year, single arm, multi-center trial to evaluate the long-term safety and efficacy of the Maestro Rechargeable System in treating obesity. The study will include an observational arm and a randomized sub-study.
- Trial name
- ReNEW (NCT03145636)
- Testing
- vBloc Maestro Rechargeable System, vBloc Achieve Weight Management Program, Control Weight Management (CWM) program
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- ReShape Lifesciences
Obesity
ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity
The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety, and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).
- Trial name
- NCT01507077
- Testing
- ZGN-440, ZGN-440 sterile diluent
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Zafgen, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.